Jonathan Peskoff
Directeur Général chez F3 Platform Biologics, Inc.
Profil
Jonathan E.
Peskoff worked as a General Partner at NextPoint Partners.
He completed his undergraduate degree at the University of Southern California.
Postes actifs de Jonathan Peskoff
| Sociétés | Poste | Début |
|---|---|---|
F3 Platform Biologics, Inc.
 F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Directeur Général | 01/01/2021 |
Anciens postes connus de Jonathan Peskoff
| Sociétés | Poste | Fin |
|---|---|---|
NextPoint Partners
 NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Private Equity Investor | 31/01/2004 |
Formation de Jonathan Peskoff
| University of Southern California | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
NextPoint Partners
NextPoint Partners Investment ManagersFinance NextPoint Partners (NextPoint Partners) is a venture capital firm founded in 1990. The firm is headquartered in Washington, District of Columbia. | Finance |
F3 Platform Biologics, Inc.
F3 Platform Biologics, Inc. BiotechnologyHealth Technology F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA. | Health Technology |
